2.

紫杉醇脂质体和紫杉醇脂质体联合奥沙利铂的疗效评定

The efficacy evaluation of Paclitaxel liposome group and Paclitaxel liposome plus oxaliplatin group

Items	Paclitaxel liposome (n=35)	Paclitaxel liposome plus oxaliplatin (n=34)	P
CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; RR: response rate; DCR: disease controlled rate; PFS: progression free survival.
CR (n)	0	0	-
PR (n)	8	12	-
SD (n)	13	12	-
PD (n)	14	10	-
RR	22.9%	35.3%	0.297
DCR	60.0%	70.6%	0.450
PFS (month)	3.5	5	0.024
1-year survival rate	28.6%	41.2%	0.724